Compare GRF & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRF | PRPO |
|---|---|---|
| Founded | 1989 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 42.0M |
| IPO Year | N/A | 2000 |
| Metric | GRF | PRPO |
|---|---|---|
| Price | $10.40 | $29.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.8K | ★ 104.8K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.97 | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $9.60 | $14.04 |
| 52 Week High | $11.85 | $33.63 |
| Indicator | GRF | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 51.16 | 75.23 |
| Support Level | $9.77 | $22.25 |
| Resistance Level | $10.58 | $33.63 |
| Average True Range (ATR) | 0.15 | 1.92 |
| MACD | -0.01 | 0.82 |
| Stochastic Oscillator | 45.65 | 100.00 |
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.